Tag:
Stimuvax
Latest Headlines
Latest Headlines
Existing drugs boost new cancer vax responses
Cancer vaccines are becoming an increasingly attractive focus of study, but there are still perils and pitfalls along the way to success. Two recent studies have looked at ways to get around these, focusing on experimental cancer vaccines boosted by existing drugs.
Oncothyreon shares routed as Stimuvax PhIII trial soldiers on
Merck KGaA told analysts today that after assessing its late-stage study for the lung cancer vaccine Stimuvax in a second interim analysis, investigators were told to push on to an ultimate read-out...
Cancer immunotherapy partners face big test with Phase III program
Merck KGaA and Oncothyreon ( $ONTY ) will learn soon whether their lung cancer vaccine has a shot at being one of the next bright lights in the cancer immunotherapy arena, with an interim analysis set
Oncothyreon awaits pivotal data on Stimuvax
Oncothyreon ($ONTY) execs are expecting interim results from a late-stage study of lung cancer vaccine Stimuvax sometime this quarter. Results from the 1,514-person trial, which is being conducted by...
UPDATED: Merck KGaA bolsters MS pipeline in $20M pact with Ono
If at first you don't succeed with a blockbuster drug, try, try again. Merck KGaA 's Serono division has worked out a pair of new deals that will bring its R&D division in league with the
Merck KGaA's pancreatic cancer vaccine ready for testing
In the quest for a cancer vaccine, Merck KGaA is again stepping into the ring. Vaximm Holding AG, the company's joint venture with a Switzerland's BB Biotech Ventures III, will start testing a
Merck KGaA gets green light on lung cancer vax trials
Merck KGaA got the green light from the FDA to restart its late-stage lung cancer program for its therapeutic vaccine Stimuvax, which had been halted after a patient in a multiple myeloma trial
Merck KGaA gets green light on lung cancer vax program
Merck KGaA got the green light from the FDA to restart its late-stage lung cancer program for its therapeutic vaccine Stimuvax, which had been halted after a patient in a multiple myeloma trial
Merck KGaA: Millipore buy 'worth every euro'
Merck KGaA's $6 billion purchase of Massachusetts-based biotechnology equipment supplier Millipore is "worth every euro," CEO Karl-Ludwig Kley told shareholders at his company's annual general
Researchers see cancer vaccine revolution on the horizon
There are already several cancer vaccine drugs nearing FDA approval. Dendreon's prostate cancer vaccine Provenge is awaiting the agency's OK, and Merck KGaA's Stimuvax is in trials for multiple
